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1. Abstract 
 
Regulatory CD4+CD25+ T (Treg) cells play a central role in the maintenance of 
immune self-tolerance and homeostasis. Although Treg cells operate through 
multiple mechanisms, it appears that the expression of the transcription factor 
Forkhead-box-P3 (FoxP3) is crucial for their function. Here we describe human 
peripheral Treg (pTreg) cells that develop from CD4+CD25- T (Tconv) cells 
following suboptimal stimulation via the T cell antigen receptor (TCR). This 
population of pTreg cells, which we call inducible Treg (iTreg) cells, is 
characterized by high FoxP3 expression, strong suppressive capacity and an 
active proliferative and metabolic state. The development of iTreg cells tightly 
depends on glycolysis, which controls FoxP3 splicing variants containing exon 2 
(FoxP3-E2), through the glycolytic enzyme enolase-1. Remarkably, iTreg cells 
suppressive activity is impaired in autoimmune diseases such as relapsing 
remitting multiple sclerosis (RR-MS), and associates with the reduction of 
FoxP3-E2 expression, secondarily to impaired glycolysis and IL-2/IL-2R/STAT-
5 signalling. These results suggest a novel mechanism that links glucose 
metabolism to the induction of specific FoxP3 splicing variants, via enolase-1, 
that directly impact on human Treg cell function, in health and in autoimmunity.  
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2. Introduction 
 
2.1 Regulatory T cells 
 
Peripheral tolerance and immune homeostasis are maintained by different cellular 
subsets. One important subset is represented by naturally occurring regulatory T (Treg) 
cells, which constitutively express the transcription factor Forkhead-box-P3 (FoxP3). 
Their dysfunction (e.g. FoxP3 gene mutation) causes fatal autoimmune disease, 
immunopathology and allergy (1). FoxP3+
 
Treg cells express CD25 (the interleukin-2 
(IL-2) receptor α-chain), and are able to suppress the activation, proliferation and 
effector functions,  as  a l so  cytokine production,  of several immune cells, including 
CD4+ and CD8+ T cells, B cells and antigen-presenting cells (APCs), natural killer 
(NK) and NKT cells, both in vitro and in vivo (1, 2). 
 IL-2 has long been thought to be a major cytokine for T cell proliferation and 
differentiation, based on its effects on T cell growth in vitro. Moreover, FoxP3, together 
with other transcription factors and coactivators/corepressors, represses the 
transcription of IL-2 in Treg cells, rendering them hyporesponsive to a classical TCR 
stimulation and highly dependent on exogenous IL-2 (mainly produced by activated 
non-Treg cells) for their maintenance and function. FoxP3 also activates the genes 
encoding Treg-associated molecules such as CD25, Cytotoxic T-Lymphocyte Antigen 
4 (CTLA-4) and Glucocorticoid-Induced TNF-Receptor-related protein (GITR) and 
confers suppressive activity to Treg cells (3).  Treg cells express numerous surface 
molecules, essential for their function. Over to CD25, they express also selectins such 
as CD62 ligand (CD62L), CC-chemokine receptor 7 (CCR7) involved in lymph-node 
homing of naive and Treg cells and programmed cell death 1 (PD-1), that is able to 
suppress T cell proliferation and induce peripheral tolerance. Several groups showed 
that Treg cells are characterized by low levels of CD127 (IL-7 receptor α-chain). For 
this reason CD127 can be a useful alternative to CD25 for the delineation and 
purification of human Treg cells (4-6). The key role of FoxP3+
 
Treg cells is to prevent 
autoimmune disease, immunopathology and allergy. They are also involved in the 
maintenance of allograft and fetal-maternal tolerance during pregnancy (7). On the 
other hand, FoxP3+
 
Treg cells can also promote tumor progression by suppressing 
effective antitumor immunity (8). For all Treg cells, FoxP3 gene is important to regulate 
development and function. Its constitutive expression is the decisive factor driving the 
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immunosuppressive function of mouse and human Treg cells. FoxP3 gene mutation 
leads to severe systemic autoimmune inflammatory diseases both in mice (Scurfy 
disease) and humans (immune dysregulation, polyendocrinopathy, enteropathy, X-
linked (IPEX) syndrome) (9-11).   
 There are two types of Treg cells: natural Treg (nTreg) cells, which develop in the 
thymus, and inducible peripheral Treg (iTreg) cells, which derive from naive CD4+ 
T cells in the periphery (Fig. 1) (12). The majority of FoxP3+ nTreg cells are produced 
by the thymus as an antigen-primed and functionally mature T cell subpopulation, 
specialized for immune suppression, and represent 5%-10% of the total peripheral 
CD4+ T cell subset. Thymic development of Treg cells requires high-affinity 
interactions between their TCR and self-peptide-MHC complexes presented by 
thymic stromal cells (13). The main role of FoxP3+ nTreg cells is to migrate to 
inflammation sites and suppress various effector lymphocytes, especially helper T (Th) 
cell subsets: Th1, Th2, Th17, and follicular Th (Tfh) cells (14, 15). 
 
 
(Jochen H. et al. Seminars in Immunology 2015) 
 
Fig. 1: Treg cells can either differentiate in the thymus from Treg-cell precursors giving rise to thymus-derived Treg cells or in the 
periphery from naive conventional FoxP3-T cells giving rise to peripherally-induced Treg cells. 
 
Previous studies have shown that TGF-β signalling and costimulation of TCR are able 
to convert CD4+CD25- conventional T cells (Tconv) in Treg cells, through the induction 
of FoxP3 expression, both in human and mice (16). However, cytokines can be 
dispensable for the generation of human iTreg cells, as these cells can also be generated 
by in vitro stimulation of Tconv cells in a cytokine-independent manner (17, 18). 
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2.2 Regulation of FoxP3 expression 
 
 FoxP3 is a master regulator of Treg cell differentiation and function and its 
expression is finely controlled at transcriptional and epigenetic level. The human 
FoxP3 gene is located at the small arm of the X-chromosome (p11.23-13.3), with 
11 different coding exons, 3 noncoding exons, and 104 introns (19). After TCR 
stimulation, different Trascription Factors (TFs) (e.g. NFAT, AP1, CREB, Runx 
and c-Rel) are able to bind specific non-coding sequences (CNS1, CNS2 and 
CNS3), and determine FoxP3 gene regulation (20). 
 DNA methylation and histone modification are two major epigenetic 
mechanisms that cooperate to modify chromatin structure. In particular, a 
conserved CpG island named Treg-specific demethylated region (TSDR) in the 
CNS2 region has also been found. 
 
 
(Piccirillo C. A. et al. Trends Mol. Med. 2012) 
 
Fig. 2: Schematic representation of FoxP3 gene structure. 
 
The methylation status of this region regulates FoxP3 expression level and the 
stability of Treg cells (Fig. 2). TSDR can lead to chromatin condensation when 
methylated, reducing the accessibility of DNA sequences and inhibiting the 
transcription of FoxP3. TSDR demethylation is essential for the transcription and 
the stability of FoxP3 in Treg cells, while partial methylation at the TSDR 
underlies the more labile FoxP3 expression seen in TGF-β-induced Treg (20, 21). 
The regulation of FoxP3 transcription is also related to the modification of the 
histone proteins. Histone acetylation is required for DNA transcription and its 
methylation inhibits DNA transcription (22). FoxP3 can be also regulated at the 
protein level by ubiquitination, phosphorylation and other post-translational 
modifications, that are important in determining the structural and physical 
properties of this protein and the complex that it forms in Treg cells, with 
significant functional consequences on its expression (23, 24). In addition, 
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through dimeric or inter-protein interactions, FoxP3 can form large protein 
complexes to regulate the expression of several genes associated with the Treg 
cell phenotype (25).  
The identification and different regulation of FoxP3 splicing variants represents 
an additional level of complexity in the biology of human FoxP3. To date, it has 
been described about 12 different FoxP3 transcripts in humans, which can give 
rise to 4 to 8 different splicing forms of the protein, with a molecular weight 
ranging from 18 to 49 kDa. However, the molecular events driving their 
expression, as well as the functional relevance of these proteins, has been not 
completely understood (26-29). The four main alternatively spliced isoforms of 
FoxP3 identified in human Treg cells are full-lenght (FoxP3FL), isoforms lacking 
exon 2 (FoxP3Δ2) or exon 7 (FoxP3Δ7) and isoforms lacking both exon 2 and 
exon 7 (FoxP3Δ2Δ7) (30). 
 
2.3 T cell metabolism 
 
Several evidences revealed that T cell metabolism changes in course of activation. 
In particular, T cells dramatically alter their metabolic activity to meet the 
increased metabolic demands of cell growth, proliferation and effector function. 
More specifically, resting naïve T cells, that have not yet encountered antigen, 
maintain low rates of glycolysis and principally use oxidative phosphorilation 
(OXPHOS) or fatty acid oxidation (FAO) to produce ATP (31). Upon activation, 
T cells preferentially use glycolysis, to sustain their proliferation and effector 
functions. In this state, T cells are considered metabolically active (Fig. 3). TCR 
signalling controls the metabolic reprogramming of naïve T cells through the up-
regulation of glucose and aminoacid transporters, facilitating nutrient uptake and 
T cell generation (32, 33). 
Interestingly, immune-mediated disorders, such as Multiple Sclerosis (MS), 
display several metabolic alterations (34). In particular, Treg cells display a high 
degree of plasticity associated with different transcriptional programs, which are 
affected by cellular metabolism (35). In vivo, human Treg cells display a high 
glycolytic rate associated with hyperactivation of the environmental sensor 
mammalian target of rapamycin (mTOR). Furthermore, in vitro-proliferating 
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human Treg cells engage both glycolysis and FAO, whereas Tconv cells 
preferentially use aerobic glycolysis to generate ATP (35). 
In vivo Treg cell metabolism is dynamic and finely regulated to ensure their 
function, being intimately connected to the oscillatory cues, such as the strenght 
of TCR signal, cytokyne milieu and nutrient availability. Treg cells are highly 
proliferative in vivo, and their state reflects higher mTOR activity and ATP levels 
as compared to Tconv cells that do not proliferate in vivo. Previous studies have 
shown that different metabolic programs are able to modulate FoxP3 expression 
and, consequently, Treg lineage differentiation in vivo and in vitro (36, 37). 
FoxP3 expression is regulated also by pyruvate metabolism, a checkpoint in 
glucose metabolism. Pyruvate dehydrogenase contributes to the transformation 
of pyruvate into mitochondrial acetyl-CoA for oxidative metabolism, that also 
control FoxP3 stability. It is well known that Treg cells use both glycolysis and 
FAO to sustain their differentiation, phenotype stabilization and function, but 
how these metabolic pathways may influence FoxP3 expresssion is not well 
understood (35).  
 
 
(Pearce E. L. et al. Science 2013) 
 
Fig. 3: T cell metabolism changes over the course of an immune response. 
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2.4 Multiple Sclerosis 
 
MS is one of the most common chronic and disabling disorders of the central 
nervous system (CNS), affecting 0.05–0.15% of Caucasians (38). The disease 
usually begins in young adulthood and the frequency is higher in women more 
than in men (2:1). In 80–90% of cases, MS starts with a relapsing–remitting 
course (RR-MS). Overtime, the number of relapses decreases, but most patients 
develop progressive neurological deficits that occur independently of relapses 
(the so-called secondary progressive phase). In 10-20% of patients, MS begins 
with a primary progressive course (PP-MS) without acute relapses. In general, 
the progression rate in RR-MS is comparable to that of PP-MS as soon as the 
patients enter the secondary progressive phase (39). Imaging studies have 
revealed differences between RR-MS and PP-MS. In patients that suffer from 
RR-MS, acute CNS lesions with spontaneous resolution are frequently detected, 
even in the absence of clinical attacks (40). These lesions are usually located in 
areas of white matter and are often characterized by a disturbance of the blood–
brain-barrier, local edema and demyelination- features that are compatible with 
an inflammatory process. By contrast, when progressing to the secondary phase 
and in patients with PP-MS, such inflammatory activity is much less evident (39). 
Global brain atrophy, however, is more dominant in the progressive stage and 
seems to correlate with disability (41, 42). These findings indicate that early in 
the disease, ongoing inflammatory activity is present in most patients and is 
responsible for the relapsing-remitting course, whereas a distinct process might 
be operative in the progressive phase of the disease, when inflammatory activity 
diminishes despite faster evolution of disability. 
 The prevalence of MS varies significantly depending on the genetic 
background of the patient (43). MS is highly prevalent in Caucasians, but only 
rarely observed in Asians or Africans. Moreover, the risk of developing the 
disease is significantly higher in family members of patients with MS (44).  These 
findings argue for a strong genetic predisposition to MS, and have prompted a 
large number of linkage and association studies to identify disease loci and 
alleles. The results of genomic screens in MS indicate that a considerable number 
of different genes, each having a relatively small contribution, are involved in the 
susceptibility to MS (45, 46). So far, only the human leukocyte antigen (HLA) 
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class II alleles DR15/DQw6 (HLA-DRB1*1501; HLA-DQB1*0601), which 
code for molecules that participate in antigen recognition by T lymphocytes, have 
been consistently associated with MS in Caucasians (47).  
    At molecular level, two steps are required to induce an immune response in the 
central nervous system (CNS): a pro-inflammatory milieu in the CNS, leading to 
upregulation of major histocompatibility complex (MHC) molecules, co-
stimulatory receptors, inflammatory cytokines and an antigen-driven acquired 
immune response. T- and B-cell responses are primed in the peripheral lymphoid 
tissue by antigens that are released from the CNS or by cross-reactive foreign 
antigens. Dendritic cells that present neural antigens are strong stimulators of T-
cell responses. Clonally expanded CD8+ T cells also invade the brain and could 
encounter their specific peptide ligand, presented by glial or neuronal cells on 
MHC class I molecules. CD4+ T cells migrate into the CNS and encounter 
antigens that are presented by microglial cells on MHC class II molecules. 
Reactivation of these cells leads to heightened production of inflammatory 
cytokines. These cytokines attract other immune cells, such as macrophages, 
which contribute to inflammation through the release of injurious immune 
mediators and direct phagocytic attack on the myelin sheath (Fig. 4) (48).  
   The immune dysregulation that characterizes the pathogenesis of MS affects, in 
particular, the number and the suppressive function of Treg cells (49-51). It has 
been recently shown that the impairment of Treg cells activity is due to an altered 
interleukin-2 (IL-2) secretion and IL-2 receptor (IL-2R)-signal trasducer and 
activator of trascription 5 (STAT5) signalling. This was also associated with a 
decreased expression of FoxP3 44- and 47- kDa splicing forms (27, 52). 
 
                   (Hemmer B. et al. Nature Reviews Neuroscience 2002) 
 
Fig. 4: Summary graph of the immunopathogenesis of MS. 
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3. Aim of the study 
 
Several evidences confirm that T cell function is intimately linked to metabolic 
programs. In particular, T cells undergo a profound metabolic reprogramming to 
cope with environmental changes that have a strong impact on proliferation, 
differentiation, regulatory and effector function (31). In this study, we aim at 
investigating the metabolic pathway controlling generation and function of 
human iTreg cells that develop from Tconv cells, following suboptimal 
stimulation via TCR. We also aim at evaluating which metabolic pathway affects 
the expression of FoxP3-E2 splicing variants, that have a greater role in providing 
suppressive ability in Treg cells (30). Finally, we would like to evaluate iTreg 
cells suppressive function in human autoimmune diseases, such as RR-MS. These 
results could unveil a novel mechanism that links metabolism to the induction of 
FoxP3-specific splicing variants that directly impact on human Treg cell function, 
in healthy and RR-MS subjects. 
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4. Material and methods 
 
4.1 iTreg cell induction 
 
iTreg cells were generated from CD4
+CD25- (Tconv) cells from healthy donors 
and RR-MS subjects and in the presence of inhibitors of specific metabolic 
pathways (1 mM 2-Deoxy-D-glucose (2DG) and 200 μM Etomoxir (Etx) (all 
from Sigma Aldrich). Briefly, after Ficoll hypaque (GE-Healthcare) gradient 
centrifugation, Tconv cells were isolated from PBMCs by negative selection 
using human CD4+CD25+ T cell kit (Invitrogen) (cell purity was > 90% by FACS 
analysis) and the cells were cultured with RPMI 1640 medium supplemented with 
100 UI/ml penicillin, 100 μg/ml streptomycin and supplemented with either 5% 
autologous serum or 5% AB human serum (Invitrogen). Cells were stimulated for 
36 hours with anti-CD3/CD28 Dynabeads (0.1 bead/cell) (Invitrogen). Tconv 
cells were then stained with the following antibodies: FITC anti-human CD4 
(clone RPA-T4), PE-Cy5 anti-human CD25 (clone M-A251) (all from BD 
PharMingen); the cells were FACS-sorted on the basis of their cell-surface CD25 
levels by using BD FACSJazz (Becton-Dikinson) (Fig. 5a). The FACS-sorted 
cells in the presence of metabolic inhibitors at 36 hours were named: iTreg-CTR, 
iTreg-2DG and iTreg-Etx cells, respectively. RR-MS and healthy subjects were 
recruited at the Università di Napoli “Federico II”, they were all naïve-to-
treatment, 40±20 years of age, with relapsing-remitting disease and with a 
Kurtzke expanded disability status score (EDSS) between 0 and 4. Healthy donors 
were age- and sex-matched with the RR-MS subjects, with no history of either 
inflammatory, endocrine, or autoimmune disease. 
4.2 Molecular signalling and Western Blot analysis 
 
FACS-Sorted iTreg-CTR, iTreg-2DG and iTreg-Etx cells were lysed after their 
isolation. Tconv cells from RR-MS and healthy subjects were lysed 24 and 36 
hours upon anti-CD3/CD28 Dynabeads (0.1 bead/cell) (Invitrogen). Total cell 
lysates and immunoblot analyses were performed as described (53). The 
antibodies used were the following: anti-phospho-STAT5 (Tyr694), anti-STAT5 
(all from Cell Signaling Technology); anti-ERK1/2 (clone H72); anti-FoxP3-all 
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(clone PCH101), anti-FoxP3-E2 (clone 150D/E4) (all from eBioscience). All 
filters were quantified by densitometric analyses as described (53). The graphs 
show the relative densitometric quantitation of each phosphorylated protein 
normalized on its total form (STAT5) or on ERK1/2 (FoxP3).  
 
4.3 Seahorse experiments 
 
The metabolic profile has been evaluated in Tconv cells and iTreg cells, in the 
presence or in the absence of anti-CD3/CD28 stimulation. Real-time 
measurements of oxygen consumption rate (OCR) and extracellular acidification 
rate (ECAR) were made using an XF-96 Extracellular Flux Analyzer (Seahorse, 
Bioscience). OCR was measured in XF media (non-buffered DMEM medium, 
containing 10 mM glucose, 2 mM L-glutamin, and 1 mM sodium pyruvate), 
under basal conditions and in response to 5 μM oligomycin, 1.5 μM of 
carbonylcyanide-4- (trifluoromethoxy)-phenylhydrazone (FCCP) and 1 μM of 
Antimycin and Rotenone (all from Sigma Aldrich). ECAR was measured in XF 
media in basal condition and in response to 10 mM glucose, 5 μM oligomycin 
and 100 mM of 2-DG (all from Sigma Aldrich). For the analysis of β-oxidation 
in all the above mentioned experimental conditions, we used the XF Palmitate-
BSA FAO substrate (Seahorse Bioscience). Briefly, β-oxidation was measured in 
FAO buffer containing NaCl 111 mM, KCl 4.7 mM, MgSO4 2.0 mM, Na2HPO4 
1.2 mM, supplemented with 2.5 mM glucose, 0.5 mM carnitine and 5 mM HEPES 
(final concentrations) pH to 7.4. We added Etx (Sigma Aldrich) (40 μM final) 15 
min before to the XF assay being initiated (t = 0). At t = 0 cells were provided 
with 30 μl of 1mM Palmitate conjugated to 0.17 mM BSA.  
 
4.4 Cytofluorimetric analysis, T cell proliferation and CFSE staining 
 
PBMCs, Tconv and iTreg cells were stained with the following monoclonal 
antibodies: FITC anti-human CD4 (clone RPA-T4), PE anti-human CD25 (clone 
M-A251), PE-Cy 5 anti-human CD25 (clone M-A251), APC anti-human CD39 
(clone TU66), APC anti-human CD71 (clone, M-A712), APC anti-human CD127 
(clone HIL-7R-M21), PE-Cy 5 anti-human CD152 (clone BNI3), APC anti-
human CD62L (clone DREG-56) and PerCP-Cy 5.5 anti-human CD279 (PD-1; 
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clone EH12.1) (all from BD PharMingen), Pe anti-human GITR (clone DT5D3, 
Miltenyi Biotec), Pe-Cy 5 anti-human CD45RO (clone UCHL1, Serotec); FITC 
anti-human CCR7 (clone 150503, R&D Systems). Subsequently cells were 
washed, fixed, permeabilized (fixation-permeabilization buffer, eBioscience) and 
stained with anti-FoxP3-PE  (clone PCH101), anti-FoxP3-PE (clone 150D/E4) 
(all from eBioscience), anti-Alexa Fluor 647 phospho-S6 ribosomal protein 
Ser235/236 (clone D57.2.2E, Cells Signaling) and anti-Ki67-FITC (clone B56, 
BD Biosciences) monoclonal antibodies. Analyses were performed employing 
the Diva software from BD and the Flow-Jo Software (Tree Star Inc.). 
The fluorescent dye CFSE (5, 6-carboxyfluorescein diacetate succinimidyl ester) 
was used at 1 μg/ml (Invitrogen). Flow cytometric analysis of CFSE dilution was 
performed by gating on CD4+ CFSE+ cells stimulated for 96 hours with anti-
CD3/CD28 Dynabeads (0.2 beads/cell) (Invitrogen) alone, or co-cultured with 
iTreg cells at different ratios (from 1:1 to 1:0.125 CD4+:iTreg).  
 
4.5 RNA extraction, qRT-PCR, qPCR and siRNA 
 
Total RNA was extracted using Triazol (Gibco/Invitrogen). cDNA was 
synthesized in a 20 μl reaction volume containing 1 μg of total RNA, 100 units 
of Superscript III Reverse Transcriptase (Invitrogen), and 1 μl of random primers 
(200 ng/μl). mRNA was reverse-transcribed for 1 hour at 50 °C, and the reaction 
was heat inactivated for 15 min at 70 °C. The products were stored at -20 °C until 
use. Quantitative (q)RT-PCR and qPCR were performed three times in three 
replicates on a 7500 RT-PCR System (Applied Biosystems) using the SYBR 
Green-detection system (FS Universal SYBR Green MasterRox; Roche Applied 
Science). The complete list of primers used is reported in Table 1. Primers for 
18S were used as internal standard control for the reactions (Table 1). To obtain 
FoxP3 and ENO1 knock down with siRNA, cells were transiently transfected, 
using a Neon® Transfection System, with siRNA in medium without serum to a 
final concentration of 10 nM and incubation was continued for 48 hours. 
Scrambled RNA, at the same concentration, was used as negative control. 
Specific siRNA against FoxP3 Exon 5; Exon 2 and scramble sequences were 
designed (Table 1). A mixture of siRNA specific for all ENO1 isoforms was used 
(target sequences, 5′-CAGUGGUGUCUAUCGAAGA-3′ and 5′-
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CCGUGACCGAGUCUCUUCA-3′) (4390821; Life Technologies). Briefly, 
Tconv cells transfection occurred at following conditions: pulse voltage, 2,400 
V; pulse width, 20 ms; pulse number, 1. Then, Tconv cells were stimulated with 
anti-CD3/CD28 beads.  
 
Table 1. Table reports specific list of primers used for PCR experiments. 
 
 
 
 
 
 
 
 
 
 
4.6 Chromatin immunoprecipitation 
 
After the appropriate treatment, cells (~7 × 105 for each antibody) were fixed for 
10 min at room temperature by the addition of 1 volume of 2% formaldehyde to 
a final concentration of 1%; the reaction was quenched by the addition of glycine 
to a final concentration of 125 mM. Fixed cells were harvested and the pellet was 
resuspended in 1 ml of lysis buffer (10 mM Tris-HCl, pH 8.0, 10 mM NaCl and 
0.2% NP-40) containing 1× protease inhibitor cocktail (Roche Applied Science). 
The lysates were sonicated to generate DNA fragments 300–600 base pairs in 
length. Sonicated samples were centrifuged and supernatants were diluted 
twofold in chromatin immunoprecipitation buffer (20 mM Tris-HCl, pH 8.0, 150 
mM NaCl, 2 mM EDTA and 1% Triton X-100). An aliquot (1/10) of sheared 
chromatin was further treated with proteinase K, then underwent extraction with 
phenol-chloroform and precipitation for measurement of DNA concentration and 
shearing efficiency (input DNA). Chromatin-immunoprecipitation reactions were 
set up according to the manufacturer's instructions (Abcam). The sheared 
chromatin was precleared by incubation for 2 hours with 1 μg of non-immune 
 PRIMERS  
FoxP3-E2 Fw 5’- CACACTGCCCCTAGTCATGG -3’ 
FoxP3-E2 Rev 5’- GCATGAAATGTGGCCTGTCCT -3’ 
FoxP3-all Transcripts 
Fw 5’- AACATGCGACCCCCTTTCACCTAC -3’ 
FoxP3-all Transcripts 
Rev 5’- GCCCCCTTCTCGCTCTCCAC -3’ 
18S Fw 5’-TCCCCATGAACGAGGAATTC-3’ 
18S Rev 5’-GGCCTCACTAAACCATCCAA-3’ 
ChIP Promoter Fw 5’- GGTTGGCCCTGTGATTTATTTTAG -3’ 
ChIP Promoter Rv 5’- GTGTGGAAGCCGCAGACCTC -3’ 
ChIP CNS2 Fw 5’- TGAGAAACCCAGTCAGAAAGG -3’ 
ChIP CNS2 Rev 5’- GGCCAGAGCTAAGAATTCTCC -3’ 
ENO1 Fw 5' TGGCAACTCTGAAGTCATCCTG 3' 
ENO1 Rev 5' TGTGGTAAACCTCTGCTCCAATG 3' 
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mouse IgG (sc-2025) and rabbit IgG (sc-2027) (both from Santa Cruz 
Biotechnology) and 20 μl of Protein A/G PLUS-Agarose (Santa Cruz 
Biotechnology) saturated with salmon sperm (1 mg/ml). Precleared chromatin 
was divided in aliquots and then was incubated for 16 hours at 4 °C with 1 μg of 
specific antibody (anti-enolase-1: 3810 (Cell Signaling Technology) or sc-15343 
(Santa Cruz Biotechnology)) and non-immune IgG (identified above). The 
immunocomplexes were recovered by incubation for 3 hours at 4 °C with 20 μl 
of protein-A/G agarose, then beads were washed with wash buffers according to 
the manufacturer's instructions (sc-2003; Santa Cruz Biotechnology), and 
immunoprecipitated DNA was recovered and analyzed by quantitative PCR 
(primers, Table 1). 
 
4.7 Statistical analysis 
 
All statistical analyses were performed with the GraphPad program (Abacus 
Concepts). All the comparisons for immunoblot, PCR, proliferation and Seahorse 
analyses were evaluated with the nonparametric Wilcoxon/Kruskal-Wallis or the 
paired two-tailed Student's t-test. For all analyses, we used two-sided tests, with 
a P value of <0.05 indicative of statistical significance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 18 
5. Results 
 
5.1 Generation of iTreg from Tconv cells following suboptimal TCR 
stimulation and their regulatory properties 
 
The induction of human iTreg cells from Tconv cells was obtained by negative 
selection of Tconv cells (90% pure) from peripheral blood mononuclear cells 
(PBMCs) of human healthy subjects activated in vitro with anti-CD3/CD28 
stimulation (0.1 bead/cell) for 36 hours, according to the scheme reported in (Fig. 
5a). After 24 hours of activation, we assessed different metabolic programs: 
glycolysis, mitochondrial respiration and fatty acid oxidation (FAO) by 
measuring the extracellular acidification rate (ECAR) and oxygen-consumption 
rate (OCR). Tconv cells increased their mitochondrial respiration rate (OCR) and 
used both glucose and fatty acids, as indicated by an increase in glycolysis and 
FAO (Fig.5 b, c). 
 Tconv cells, 36 hours post activation, were sorted by flow cytometry in three 
different subsets, on the basis of their cell-surface CD25 levels. CD25 high 
(CD25high), CD25 intermediate (CD25int) and CD25 low (CD25low) were 
subsequently analysed for their proliferative rate (using the Ki67 marker), 
metabolic asset (measuring the levels of p-S6, a downstream target of the 
mammalian-target of rapamycin, mTOR) and FoxP3 levels (Fig. 5d, middle 
panels) and we found that CD25high cells had highest levels of all these markers 
(Fig. 5d, middle panels).  In addition, we investigated the ability of these subsets 
to suppress the proliferation of CD4+CFSE-labelled T cells activated in vitro with 
anti-CD3/CD28 (Fig. 5d, right panels). We found that CD25high also had the 
strongest suppressive activity (Fig. 5d, right panels). These results indicated that 
human iTreg cells could be induced from Tconv cells stimulated by weak 
engagement of TCR in the absence of exogenous cytokines and that they retained 
their suppressive capacity over time. 
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Fig. 5: Metabolic state and regulatory properties of human iTreg cells. (a) Schematic representation of the 
experimental procedure used to generate human iTreg cells from human activated Tconv cells. (b) ECAR and OCR of 
Tconv cells after 24 hours of in vitro stimulation with anti-CD3/CD28. (c) OCR quantifying FAO of Tconv cells after 24 
hours of in vitro stimulation with anti-CD3/CD28. (d) (left) Representative flow cytometry plots of CD4+CD25+ T cells 
FACS-sorted on the basis of surface CD25 expression; (middle) percentage of expression of Ki67, p-S6 and FoxP3 in 
CD25hi, CD25int and CD25low. Numbers in plots indicate percent CD25hi cells (top), CD25int cells (middle) or CD25low 
cells (bottom) or mean fluorescence intensity (MFI) (in parentheses) of CD25 in those cells; (right) proliferation of 
CD4+CFSE-labelled T cells stimulated for 96 hours in vitro with anti-CD3/CD28 (filled gray histograms), in the presence 
of FACS-sorted CD25hi, CD25int and CD25low (black lines in histograms), respectively and (right) percent proliferation of 
CD4+ T cells in those conditions. (b, c) Data are from one experiment representative of three experiments with technical 
duplicates (mean ± s.e.m). (d) (left) One experiment representative of seven experiments; (middle) mean ± s.e.m. of seven 
independent experiments, *P < 0.05 Wilcoxon matched-pairs test; (right) one representative of three experiments.  
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5.2 Effect of either glycolysis or FAO inhibition on the generation, suppressive 
function and phenotypical markers of iTreg cells 
 
There is growing evidence that show how different metabolic pathways are 
involved in the generation and activation of T cells (54-56). For this reason we 
activated Tconv cells in the presence or in the absence of specific inhibitors of 
glycolysis and fatty acid oxidation (FAO), 2-Deoxy-D-Glucose (2DG) and 
Etomoxir (Etx), respectively with the same procedure shown in figure 5a. We 
found that both inhibitors significantly affected the ability to up-regulate CD25 
(Fig. 6a, left panels). Strikingly, FoxP3 expression was markedly reduced in 
CD25high T cells generated in the presence of 2DG and sorted by flow cytometry 
(iTreg-2DG cells), but was increased in CD25high T cells generated in the presence 
of Etx (iTreg-Etx cells), when compared with untreated CD25high T cells (iTreg-
CTR cells) (Fig. 6a, right panels). To determine whether metabolic perturbation 
associated with altered regulatory function, iTreg-2DG cells and iTreg-Etx cells 
were tested for their ability to suppress, at different ratios, the proliferation of 
CD4+CFSE-labelled T cells activated in vitro with anti-CD3/CD28. We found 
that iTreg-2DG cells showed a reduced suppressive function at all the different 
ratios analysed, whereas iTreg-Etx cells exhibited a higher suppressive activity 
when compared with iTreg-CTR cells (Fig. 6b). These findings suggest that 
glycolysis, but not fatty acid oxidation, is required for generation and suppressive 
function of human iTreg cells. Inhibition of glycolysis with 2DG reduced the 
expression of several Treg cell markers such as CTLA-4, PD-1, CD39, GITR and 
CD71, as well as the phosphorylation of S6 (Fig. 6c), whereas Etx had a similar 
effect on PD-1, CD39 and phosphorylation of S6, slightly reduced CD71 and 
CCR7 but preserved the expression of CTLA-4 and up-regulated GITR levels 
compared to iTreg-CTR cells (Fig. 6c). By measuring ECAR and OCR (FAO and 
oxidative phosphorylation) of FACS-sorted iTreg cells, we found that iTreg-2DG 
cells had an impaired glycolytic capacity and mitochondrial respiration relative 
to that of iTreg-CTR cells (Fig. 6d, right and left panels), with FAO rates similar 
to those of iTreg-CTR cells (Fig. 6e, left panel), while Etx treatment affected 
FAO (Fig. 6c, right panel) and mitochondrial respiration (Fig. 6d, right panel), 
but preserved glycolysis when compared to iTreg-CTR cells (Fig. 6d, left panel). 
These data suggest that inhibition of glycolysis profoundly affects the generation 
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and function of human iTreg cells, particularly impairing the induction of FoxP3 
and Treg specific molecular and surface markers. 
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Fig. 6: Isolation, phenotypical characterization and metabolic programs of iTreg-CTR, iTreg-2DG and iTreg-Etx 
cells. (a) (left) Representative flow cytometry plots of CD4+CD25hi  iTreg-CTR, iTreg-2DG and iTreg-Etx cells FACS-
sorted; (right) CD4+FoxP3+ T cells of FACS-sorted iTreg cells derived from each different condition. Numbers in plots 
(top left corner) indicate percent CD25+ cells or MFI (in parentheses) of CD25 (left) or percent FoxP3+ cells or MFI (in 
parentheses) of FoxP3 (right). (b) Schematic representation of suppression of T cell proliferation, at 96 hours, by FACS-
sorted iTreg cells derived from different culture condition at different ratios (from 1:1 to 1:0.125). (c) Representative flow 
cytometry plots of Treg cell–specific markers in iTreg-CTR, iTreg-2DG and iTreg-Etx cells. (d) (left) ECAR and (right) 
OCR of iTreg-CTR, iTreg-2DG and iTreg-Etx cells stimulated for 24 hours in vitro with anti-CD3/CD28. (e) (left) OCR 
quantifying FAO of iTreg-CTR and iTreg-2DG or (right) of  iTreg-CTR and iTreg-Etx, stimulated for 24 hours in vitro 
with anti-CD3/CD28, in the presence of palmitate alone or palmitate plus inhibitor. (a) Data are representative of three 
independent experiments; (b) mean ± s.e.m. of three independent experiments with technical triplicates, *P < 0.005 and 
**P < 0.005 by by Wilcoxon matched-pairs test; (c) One experiments representative of six; (d, e) one experiment 
representative of two experiments with technical duplicates (mean ± s.e.m). 
 
 
5.3 Glycolysis influences FoxP3-E2 expression and suppressive function 
 
We evaluated which specific metabolic program could control regulatory 
function in iTreg cells, acting on the expression of FoxP3 and its splicing variants. 
To this aim, we measured all FoxP3 splicing forms by dissecting their expression 
with two specific antibodies, one recognizing all FoxP3 splicing variants 
(recognized through a common epitope of the FoxP3 amino-terminous, clone 
PCH101), the other specific for the FoxP3-E2 variant (recognized an epitope 
contained in the E2 only, clone 150/E4). iTreg-2DG cells had a marked reduction 
of both the 47- and 44- kDa splicing forms, while their levels were not affected 
in iTreg-Etx cells as compared to iTreg-CTR (Fig, 7a, b). We also confirmed 
these findings by quantitative RT-PCR (data not shown). Since we have shown 
that iTreg-2DG cells displayed an impaired suppressive capacity and this 
associated with a reduced expression of FoxP3-E2 (Fig. 6b and 7b, 
respectively), we studied whether FoxP3-E2 was indispensable for the regulatory 
function of iTreg cells by using small interfering mRNA (siRNA). We designed 
small interfering mRNA (siRNA) specific for the exon 2 domain (siRNA-E2) and 
for exon 5 (E5), a sequence common to all FoxP3 transcripts (siRNA-E5), to 
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address whether FoxP3-E2 protein was indispensable for iTreg regulatory 
function. Therefore, iTreg cells were generated in the presence of these different 
siRNA and tested for their ability to suppress the proliferation of CD4+CFSE-
labelled T cells stimulated with anti-CD3/CD28. We found that iTreg cells 
generated in the presence of siRNA-E2 had a reduced suppressive ability at all 
the different ratios analysed, whereas iTreg cells generated in the presence of 
siRNA-E5 had no significant differences in their suppressive activity when 
compared to iTreg cells generated in the presence of scramble sequences siRNA 
(siRNA-Scr) (Fig. 7c). Our results suggest that glucose metabolism controls the 
FoxP3-E2 splicing variant which results to be indispensable for an appropriate 
iTreg cells suppressive function to occur. 
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Fig. 7: Glycolysis controls the expression of FoxP3Exon2 splicing forms which are indispensable for suppressive 
function to occur. (a) Schematic representation of FoxP3 mRNA splicing variants. The exons are indicated by green 
boxes (light green represent 5' and 3' untranslated regions (UTR), dark green represent coding DNA sequence and blue 
poly(A) sites), red boxes represents FoxP3 promoter. The spliced exon 2 in Foxp3-Δ2 are indicated by red arrow. (b) 
Western blotting analysis of FoxP3 protein levels in iTreg-CTR, iTreg-2DG and iTreg-Etx cells. The gels show expression 
of FoxP3 protein detected by using two mAbs recognizing different epitopes, (left) one reacting with a common epitope 
of the amino-terminous (PCH101), and (right) the other reacting with an epitope contained exon 2 (150D/E4). Total protein 
levels are assessed by measuring total Erk 1/2 levels. The graphs show relative densitometric quantitation of two different 
FoxP3 forms. (c) Suppression of CD4+CFSE-labelled T cells proliferation by iTreg cells generated in the presence of three 
different small interfering mRNA (siRNA) one specific for a scramble sequence (siRNA-Scr, black square), another for 
exon 5 (siRNA-E5, gray triangle) and another for the exon 2 (siRNA-E2, grey triangle), respectively, at a ratio of 1:1 or 
1:0.5. (b) Data represent mean ± s.e.m. (n = 10), *P < 0.005 by two-tailed Student's t-test; (c) mean ± s.e.m. of three 
independent experiments with 3 technical replicates in each (n = 9 replicates), *P < 0.05 by Wilcoxon matched-pairs test. 
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5.4 Enolase-1 controls FoxP3-E2 expression 
 
Different isoforms of enolase-1, a key glycolytic enzyme, can bind DNA and 
regulate gene expression in several experimental system (57-59). In particular, 
the glycolytic enzyme enolase-1 (48-kDa) and the transcriptional repressor MBP-
1 (37-kDa) arise from the gene ENO1 through the use of alternative translation 
start sites present on ENO1 mRNA (50, 60). Evidence from literature shows that 
enolase-1 isoforms control multifunctional activities within the cells, ranging 
from glycolytic activity in the cytoplasm to gene regulation in the nucleus (50, 
60). To evaluate whether enolase-1 could be involved in the regulation 
of  FoxP3 in iTreg cells, we performed chromatin-immunoprecipitation analysis 
that revealed that enolase-1 was recruited on both FoxP3 promoter and on CNS2 
region. This recruitment was greater in iTreg-2DG cells than iTreg-CTR cells 
(Fig. 8a); on the contrary the association between enolase-1 and FoxP3 promoter 
was lower in iTreg-Etx cells than in iTreg- CTR cells, but in association with 
FoxP3 CNS2 was similar in iTreg-Etx cells and iTreg-CTR cells (Fig. 8a). To 
understand whether enolase-1 directly controlled the splicing of mRNA, we 
silenced ENO1 by using ENO1-specific siRNA (siRNA-ENO1) during the 
generation of iTreg cells. We found that silencing of ENO1 restored the 
expression of FoxP3 mRNA in iTreg-2DG cells (evaluated through qRT-PCR). 
(Fig. 8b). Specifically, silencing of ENO1 in iTreg-2DG cells led to the recovery 
of all FoxP3 transcripts and an even greater recovery of FoxP3-E2 mRNA (Fig. 
8a). In addition, the level of FoxP3-E2 mRNA was significantly higher, whereas 
the level of total FoxP3 mRNA was slightly lower in iTreg-CTR cells generated 
in the presence of siRNA-ENO1 than in those generated with siRNA-Scr (si-RNA 
that does not inhibit FoxP3 expression) (Fig. 8a). Together these data suggest that 
enolase-1 specifically repressed the expression of FoxP3-E2 in iTreg cells. 
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Fig. 8: Localization of enolase-1 on FoxP3 promoter and CNS2 controls FoxP3-E2 expression. (a) localization of 
enolase-1 on the promoter (left) and CNS2 (right) in Tconv, iTreg-CTR, iTreg-2DG and iTreg-Etx cells, observed by 
chromatin immunoprecipitation with mAb to enolase-1. (b) qRT-PCR analysis of all FoxP3 transcripts (left) and FoxP3-
E2 mRNA (right) in iTreg-CTR and iTerg-2DG cells generated in the presence of siRNA-Scr or siRNA-ENO1; results 
were normalized to those of control 18S rRNA and are presented relative to those of iTreg-CTR cells treated with siRNA-
Scr. (a) Data are four independent experiments with technical duplicates (mean ± s.e.m.), *P < 0.05, **P < 0.005, ***P 
< 0.0005 by two-tailed Student's t-test; (b) mean ± s.e.m. of four independent experiments, *P < 0.05, ***P < 0.0005 by 
two-tailed Student's t-test. 
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5.5 Altered glycolysis and impaired suppressive function of human iTreg cells 
from RR-MS subjects 
 
To investigate the physiological impact of our findings in autoimmunity, we 
evaluated the generation, phenotype and functional properties of iTreg cells from 
Tconv cells of naïve-to-treatment relapsing-remitting multiple sclerosis (RR-MS) 
subjects. Firstly, we observed that glycolysis, during Tconv cells activation, was 
impaired in RR-MS subjects when compared with healthy controls. (Fig. 9a). 
Moreover we found that iTreg cells from RR-MS subjects showed reduced levels 
of FoxP3-E2, CTLA-4, PD-1, GITR, CD71 and phosphorylation of S6, when 
compared with iTreg cells generated from healthy subjects (Fig. 9b). Since we 
have previously reported that generation and function of iTreg cells was strictly 
dependent on glycolysis, iTreg cells from both RR-MS and healthy controls were 
FACS-sorted and tested for their ability to suppress the proliferation of 
CD4+CFSE-labelled T cells activated in vitro with anti-CD3/CD28. We observed 
that iTreg cells from RR-MS subjects showed a reduced suppressive function at 
both ratios when compared to iTreg cells from healthy individuals (Fig. 9c). To 
assess whether these phenomena associated with altered IL-2/IL-2R/STAT5 
signalling pathway, which is pivotal for the generation and the homeostasis of 
Treg cells (27), we performed western blotting analysis of Tconv cells from RR-
MS and healthy subjects, activated in vitro with suboptimal anti-CD3/CD28 
stimulation for 24 and 36 hours. There was a profound delay in the induction of 
both 47- and 44 kDa FoxP3 forms in RR-MS subjects (at 24 hours) which 
correlated with an impairment of p-STAT5 signalling (Fig. 9d). These data 
suggest that the normal glycolytic rate of Tconv cells from healthy subjects 
determins the generation of functional iTreg cells that express correct amount of 
FoxP3-E2. On the contrary, RR-MS subjects, in whitch there is an impairment of 
glycolysis, have a reduced expression of FoxP3-E2 that correlates with reduced 
suppressive capacity of iTreg cells. 
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Fig. 9: Impaired glycolysis, altered FoxP3-E2 expression, reduced IL-2/IL-2R/STAT5 signalling in iTreg cells from 
RR-MS subjects. (a) ECAR of Tconv cells isolated from RR-MS subjets (n = 5) and healthy subjects (n = 12) after 24 
hours in vitro stimulation with anti-CD3/CD28. (b) Representative dot plots showing CD25, FoxP3-E2 and other Treg 
cell markers in FACS-sorted iTreg cells from healthy and RR-MS subjects. Shown are the MFI and percent of expression 
of markers in iTreg cells from control (black lines) and from RR-MS subjects (grey full lines). (c) Suppression of T cell 
proliferation (96 hours) by FACS-sorted iTreg cells from control and RR-MS subjects, at different ratio (1:1 and 1:0.5). 
(d) Western blot of IL-2/IL-2R/STAT5 signalling and 44-47-kDa FoxP3 protein forms, after 24 and 36 hours of in vitro 
stimulation with anti-CD3/CD28 of Tconv cells from RR-MS and healthy subjects. Graphs show relative densitometric 
quantitation of FoxP3 bands normalized on total ERK 1/2 and p-STAT5 normalized on its total form. (a) Data shown as 
mean ± s.e.m.; (b) representative of four independent experiments; (c) data from four independent experiments (mean ± 
s.e.m.), *P < 0.05 by Wilcoxon matched-pairs test; (d) results are from three independent experiments in duplicates, 
performed on two healthy and two RR-MS subjects (mean ± s.d.); *P < 0.05, **P < 0.05 by Wilcoxon test. 
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6. Discussion 
 
This study shows that human iTreg cells can be generated de novo from non 
regulatory Tconv cells following suboptimal TCR stimulation and without the 
requirement of exogenous regulatory-type cytokines, thus providing evidence 
that TCR signal strenght is a critical determinant of FoxP3 induction and Treg 
cell generation (61, 62). We find that iTreg cells represent the highly proliferative 
and metabolically active fraction of activated T cells, whose generation mainly 
relies on glycolysis. Indeed, 2DG (a glycolytic inhibitor) affects FoxP3 induction, 
reduces expression of Treg cell markers (CTLA-4, PD-1, GITR, CD39, CD71 
and p-S6) and impairs suppressive function of iTreg cells. The inhibition of FAO 
with Etx increses FoxP3 expression and the generation of iTreg cells with strong 
regulatory properties. These results are in agreement with recent literature 
showing that the engagement of distinct metabolic pathways controls T cell 
function and differentiation (54-56). This study also demonstrates the crucial role 
of glycolysis in the modulation of the expression of specific FoxP3 splicing forms 
that are indispensable for iTreg cell suppressive function. We find that 2DG 
specifically affects the 47- and 44-kDa splicing form: 2DG treatment is able to 
reduce the exon 2 containing FoxP3 splicing forms, which we show necessary for 
the regulatory function of iTreg cells (reduced suppressive ability in iTreg-2DG 
cells). iTreg-Etx have higher expression of FoxP3-E2 at protein level (but also as 
mRNA), and this associates with stronger suppressive function. 
 Several factors are able to bind the regulatory regions of FoxP3 gene, regulate 
gene expression thanks to transient modification of chromatin. Among them, 
enolase-1, a key glycolytic enzyme, has been reported to bind DNA and to 
suppress gene expression (57, 58). Here we describe that enolase-1 is selectively 
recruited on the promoter and CNS2 region of FoxP3 gene in iTreg-2DG cells to 
act as a FoxP3 gene repressor. On the contrary, iTreg-Etx cells have reduced 
amount of enolase-1 on FoxP3 gene, thus accounting for the higher levels of 
FoxP3-E2 observed. In all, the evidence that glycolysis and FAO differentially 
control expression of FoxP3 splicing variants in iTreg cells, and their suppressive 
ability, indicates that a specific metabolic program is required for generation of 
Treg cells following Tconv cell activation. 
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To investigate the impact of our findings in human autoimmunity, we also 
evaluated the generation rate, the phenotype and the functional properties of iTreg 
cells from Tconv cells of RR-MS subjects. iTreg cells from these subjects have a 
marked reduced suppressive function, associated with a specific impairment of 
FoxP3-E2 expression, secondary to a defect in glycolysis following Tconv cell 
activation. At the molecular levels, altered FoxP3 induction associates with 
functional impairment of IL-2/IL-2R/STAT5 signalling pathway in iTreg cells 
from RR-MS subjects, which has a pivotal role in FoxP3 induction, generation 
and homeostasis of Treg cells (63, 64). 
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7. Conclusions 
 
In conclusion, this study shows that distinct metabolic pathways can contribute 
to the generation of human iTreg cells from previously non regulatory Tconv 
cells, after suboptimal-low TCR engagement. The newly generated iTreg cells 
represented a small fraction of the activated CD4+ T cells with the strongest 
proliferation and metabolic activity associated with marked FoxP3 expression 
and suppressive function. Glycolysis, via the glycolytic enzyme enolase-1, had a 
crucial role in the generation and function of these cells, through the modulation 
of the FoxP3-E2 splicing form, which was indispensable for their suppressive 
function. Moreover, the defect of the Treg cell compartment in MS could be 
ascribed to a disequilibrium between T cell activation and induction of specific 
FoxP3 splice variants, secondary to an impaired glycolysis and IL-2/IL-
2R/STAT5 signalling. 
Restoring glycolysis in Tconv cells could help to improve immune tolerance and 
could have potential therapeutic implications in MS and in other autoimmune 
diseases. 
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